Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
15 hedge funds and large institutions have $1.94M invested in Acorda Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 15 closing their positions.
281% more call options, than puts
Call options by funds: $347K | Put options by funds: $91K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
48% less capital invested
Capital invested by funds: $3.71M → $1.94M (-$1.77M)
48% less funds holding
Funds holding: 29 → 15 (-14)
87% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$15.4K |
| 2 |
Morgan Stanley
New York
|
+$9.47K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.94K |
| 4 |
BlackRock
New York
|
+$36 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
-$416K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$128K |
| 3 |
Millennium Management
New York
|
-$102K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$93.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$82.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| – | -$9K | -771 | Closed |
|
27
Two Sigma Advisers
New York
| – | -$8.61K | -735 | Closed |
|
|
SQA
28
Simon Quick Advisors
Morristown,
New Jersey
| – | -$8.42K | -719 | Closed |
|
|
HF
29
HRT Financial
New York
| – | -$7K | -626 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$3.53K | -301 | Closed |
|
ACOR Hedge Fund Activity: Q2 2023 in Review
15 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2023, worth a combined $1.94M — down 48% from $3.71M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ACOR and 2 opened new positions — a net loss of 13 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $15.4K. The largest seller was Davidson Kempner Capital Management, cutting an estimated $416K.
- 15 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2023, down from 29 in Q1 2023.
- Funds reported $1.94M of Acorda Therapeutics stock for Q2 2023, down 48% quarter-over-quarter.
- 2 funds opened new Acorda Therapeutics positions in Q2 2023 and 15 closed out, a net change of -13 holders.
- The largest Acorda Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $15.4K added.
- The largest Acorda Therapeutics seller in Q2 2023 was Davidson Kempner Capital Management, an estimated $416K sold.
Based on aggregated 13F filings for Q2 2023.